Cogent Biosciences, Inc. (COGT)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch COGT
See up to 3 months of COGT. The 7-day demo opens the 1M and 3M ranges and puts COGT on your watchlist.
Start 7-day demoLatest COGT insider trades
About Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. files with the SEC under CIK 0001622229 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
COGT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 45,510 | $1.69M |
| Grant or award | 1 | 759 | |
| Option exercise | 4 | 91,020 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
COGT insider transactions (Form 4)
5428 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Karen Jean Ferrante - Director | Grant or award | Stock Option (Right to Buy) | 759 | $0.00 footnote F1 | - | |
| ||||||
| Arlene Morris - Director | Option exercise | Common Stock | 41,927 | $5.64 | $236K | |
| Arlene Morris - Director | Option exercise | Common Stock | 3,583 | $2.52 | $9K | |
| Arlene Morris - Director | Open-market sale | Common Stock | 42,349 | $37.09 footnote F2 | $1.57M | |
| Arlene Morris - Director | Open-market sale | Common Stock | 3,161 | $37.54 footnote F3 | $119K | |
| Arlene Morris - Director | Option exercise | Stock Option (Right to Buy) | 41,927 | $0.00 | - | |
| Arlene Morris - Director | Option exercise | Stock Option (Right to Buy) | 3,583 | $0.00 | - | |
| ||||||
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 627 | $0.00 footnote F1 | - | |
| ||||||
| Peter Evan Harwin | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Christopher W. Cain | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
 Todd Shegog | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Arlene Morris | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Matthew Ros | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Andrew R. Robbins - Officer | Gift | Common Stock | 160,000 | $0.00 | - | |
| Andrew R. Robbins - Officer | Gift | Common Stock | 160,000 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 686 | $0.00 footnote F1 | - | |
| ||||||
| Fairmount Funds Management LLC - Director | Other | Common Stock | 7,000,000 | - footnote F1 | - | |
| Fairmount Funds Management LLC - Director | Open-market sale | Common Stock | 7,000,000 | $34.66 | $242.62M | |
| Fairmount Funds Management LLC - Director | Other | Series A Convertible Preferred Stock | 28,000 | $0.00 | - | |
| ||||||
| Fairmount Funds Management LLC - Director | Open-market sale | Common Stock | 3,500,000 | $36.40 | $127.40M | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 643 | $0.00 | - | |
| Evan Kearns - Officer | Open-market sale | Common Stock | 65,000 | $38.70 footnote F1 | $2.52M | |
| ||||||
| John L. Green - Officer | Open-market sale | Common Stock | 77,000 | $38.68 footnote F1 | $2.98M | |
| ||||||
| Jessica Sachs - Officer | Open-market sale | Common Stock | 82,642 | $38.70 footnote F1 | $3.20M | |
| ||||||
| John Edward Robinson - Officer | Open-market sale | Common Stock | 90,000 | $38.74 footnote F1 | $3.49M | |
| ||||||
| John Edward Robinson - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| John Edward Robinson - Officer | Grant or award | Common Stock | 320,000 footnote F2 | $0.00 | - | |
| John Edward Robinson - Officer | Tax withholding / forfeiture | Common Stock | 139,998 footnote F3 | $39.45 | $5.52M | |
| John Edward Robinson - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| ||||||
| Andrew R. Robbins - Officer | Grant or award | Common Stock | 185,000 footnote F1 | $0.00 | - | |
| Andrew R. Robbins - Officer | Grant or award | Common Stock | 840,000 footnote F2 | $0.00 | - | |
| Andrew R. Robbins - Officer | Tax withholding / forfeiture | Common Stock | 367,497 footnote F3 | $39.45 | $14.50M | |
| Andrew R. Robbins - Officer | Grant or award | Stock Option (Right to Buy) | 245,000 | $0.00 | - | |
| ||||||
| Cole Pinnow - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Cole Pinnow - Officer | Grant or award | Common Stock | 214,000 footnote F3 | $0.00 | - | |
| Cole Pinnow - Officer | Tax withholding / forfeiture | Common Stock | 94,800 footnote F4 | $39.45 | $3.74M | |
| Cole Pinnow - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| ||||||
| Evan Kearns - Officer | Grant or award | Common Stock | 40,000 footnote F1 | $0.00 | - | |
| Evan Kearns - Officer | Grant or award | Common Stock | 260,000 footnote F2 | $0.00 | - | |
| Evan Kearns - Officer | Tax withholding / forfeiture | Common Stock | 125,602 footnote F3 | $39.45 | $4.95M | |
| Evan Kearns - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| ||||||
| Jessica Sachs - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Jessica Sachs - Officer | Grant or award | Common Stock | 320,000 footnote F2 | $0.00 | - | |
| Jessica Sachs - Officer | Tax withholding / forfeiture | Common Stock | 154,716 footnote F3 | $39.45 | $6.10M | |
| Jessica Sachs - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| ||||||
| John L. Green - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| John L. Green - Officer | Grant or award | Common Stock | 300,000 footnote F2 | $0.00 | - | |
| John L. Green - Officer | Tax withholding / forfeiture | Common Stock | 145,007 footnote F3 | $39.45 | $5.72M | |
| John L. Green - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| ||||||
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 1,642 | $0.00 footnote F1 | - | |
| ||||||
| Fairmount Funds Management LLC - Director | Open-market purchase | Common Stock | 2,777,777 | $9.00 | $25.00M | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 3,314 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 2,034 | $0.00 | - | |
Item 1.01
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Recent COGT Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| ARLENE MORRIS | Director | 45,510 | $1.67M | View on EDGAR |
COGT insider trading FAQ
What is the latest insider trade for COGT?
Cogent Biosciences, Inc. (COGT) had 2 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for COGT runs to 28 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying COGT stock?
No insider purchases of COGT were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling COGT stock?
2 insider sales of COGT were filed in the last 90 days, totaling $1.69M.
Where can I see COGT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects COGT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Karen Jean Ferrante view on EDGAR
- - Arlene Morris view on EDGAR
- - Karen Jean Ferrante view on EDGAR
- - Peter Evan Harwin view on EDGAR
- - Karen Jean Ferrante view on EDGAR
- - Christopher W. Cain view on EDGAR
- - Todd Shegog view on EDGAR
- - Arlene Morris view on EDGAR
- - Matthew Ros view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where COGT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow COGT with a 7-day demo
- COGT on your watchlist
- Every COGT Form 4 filing on record
- Up to 3 months of COGT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
